Important Downstream Molecule Research Articles

Growth arrest induces primary-cilium formation and sensitizes IGF-1-receptor signaling during differentiation induction of 3T3-L1 preadipocytes

The first stage of 3T3-L1 adipocyte differentiation is growth arrest, which is achieved by contact inhibition at confluence. In growth-arrested confluent 3T3-L1 preadipocytes, alpha-tubulin acetylation and primary-cilium formation were induced. The blockade of primary-cilium formation by suppressing IFT88 or Kif3a inhibited 3T3-L1 adipocyte differentiation. IGF-1 (IGF-I)-receptor signaling, which is essential for differentiation induction, was sensitized by the formation of a primary cilium in confluent 3T3-L1 preadipocytes. The receptor located in primary cilium was more sensitive to insulin stimulation than that not located in cilia. During cilium formation, insulin receptor substrate 1 (IRS-1), one of the important downstream signaling molecules of the IGF-1 receptor, was recruited to the basal body at which it was phosphorylated on tyrosine by the receptor kinase in cilia. Akt-1, an important signal molecule of the IGF-1 receptor in adipocyte differentiation, was also activated at the basal body. These IGF-1-receptor signaling processes were all inhibited in IFT88- or Kif3a-knockdown cells. Thus, the primary cilium and its basal body formed an organized signaling pathway for the IGF-1 receptor to induce adipocyte differentiation in confluent 3T3-L1 preadipocytes.

Effect of butyrate on the heregulin/ErbB-mediated proliferation of human colorectal cancer cells

The expression of ErbB proteins, together with heregulin, was found to be increased in colon cancer cells compared with normal mucosa, and heregulin-stimulated activation of ErbB signaling was observed to contribute to the proliferation of colon cancer cells. Butyrate produced during the fermentation of fiber by intestinal bacteria is known to exert diverse anticancer effects, including the induction of differentiation, cell cycle arrest and growth suppression in human colon cancer cells. In this study, we investigated whether butyrate affects the heregulin/ErbB-mediated proliferation of colon cancer cells. The growth of human CaCo-2 and SNU-C4 colon cancer cells, which express ErbB1-4 proteins, was stimulated by heregulin in a concentration-dependent manner. Pretreatment with sodium butyrate abolished heregulin-stimulated proliferation in both cell lines. Although butyrate did not alter ErbB protein expression and activation, it did block the prolonged activation of Akt and Erk1/2, which are known to be important ErbB downstream molecules mediating heregulin-stimulated proliferation. Our data suggest that the inhibitory effects of butyrate on the heregulin-stimulated proliferation of colorectal cancer cells are, in part, associated with the suppression of the Akt and Erk signaling pathway. Butyrate may act as a preventive and therapeutic agent in the progression of colorectal cancer through the regulation of heregulin-stimulated mitogenic signaling.

C-Jun/AP-1 pathway-mediated cyclin D1 expression participates in low dose arsenite-induced transformation in mouse epidermal JB6 Cl41 cells

Arsenic is a well-documented human carcinogen associated with skin carcinogenesis. Our previous work reveals that arsenite exposure is able to induce cell transformation in mouse epidermal cell JB6 Cl41 through the activation of ERK, rather than JNK pathway. Our current studies further evaluate downstream pathway in low dose arsenite-induced cell transformation in JB6 Cl41 cells. Our results showed that treatment of cells with low dose arsenite induced activation of c-Jun/AP-1 pathway, and ectopic expression of dominant negative mutant of c-Jun (TAM67) blocked arsenite-induced transformation. Furthermore, our data indicated that cyclin D1 was an important downstream molecule involved in c-Jun/AP-1-mediated cell transformation upon low dose arsenite exposure, because inhibition of cyclin D1 expression by its specific siRNA in the JB6 Cl41 cells resulted in impairment of anchorage-independent growth of cells induced by low dose arsenite. Collectively, our results demonstrate that c-Jun/AP-1-mediated cyclin D1 expression is at least one of the key events implicated in cell transformation upon low dose arsenite exposure.

Use of Akt Inhibitor and a Drug-resistant Mutant Validates a Critical Role for Protein Kinase B/Akt in the Insulin-dependent Regulation of Glucose and System A Amino Acid Uptake

Protein kinase B (PKB)/Akt has been strongly implicated in the insulin-dependent stimulation of GLUT4 translocation and glucose transport in skeletal muscle and fat cells. Recently an allosteric inhibitor of PKB (Akti) that selectively targets PKBalpha and -beta was reported, but as yet its precise mechanism of action or ability to suppress key insulin-regulated events such as glucose and amino acid uptake and glycogen synthesis in muscle cells has not been reported. We show here that Akti ablates the insulin-dependent regulation of these processes in L6 myotubes at submicromolar concentrations and that inhibition correlates tightly with loss of PKB activation/phosphorylation. Similar findings were obtained using 3T3-L1 adipocytes. Akti did not inhibit IRS1 tyrosine phosphorylation, phosphatidylinositol 3-kinase signaling, or activation of Erks, ribosomal S6 kinase, or atypical protein kinases C but significantly impaired regulation of downstream PKB targets glycogen synthase kinase-3 and AS160. Akti-mediated inhibition of PKB requires an intact kinase pleckstrin homology domain but does not involve suppression of 3-phosphoinositide binding to this domain. Importantly, we have discovered that Akti inhibition is critically dependent upon a solvent-exposed tryptophan residue (Trp-80) that is present within the pleckstrin homology domain of all three PKB isoforms and whose mutation to an alanine (PKB(W80A)) yields an Akti-resistant kinase. Cellular expression of PKB(W80A) antagonized the Akti-mediated inhibition of glucose and amino acid uptake. Our findings support a critical role for PKB in the hormonal regulation of glucose and system A amino acid uptake and indicate that use of Akti and expression of the drug-resistant kinase will be valuable tools in delineating cellular PKB functions.

High expression of TCF-4 positively correlated with lung cancer progression.

TCF-4 is an important downstream molecule of Wnt signaling pathway, but studies on the expression level and significance of TCF-4 in lung cancer were still limited. The aim of this study is to examine the expression level of TCF-4 in lung cancer tissues and cell lines, and analyze its relationship with clinicopathologic characteristics and biological behavior of lung cancers. TCF-4 expression was examined in 120 lung cancer specimens and 10 corresponding normal lung specimens using immunohistochemistry (S-P method). Immunofluorescence was used to examine the TCF-4 protein expression level and subcellular localization in lung cancer cells and HBE (human normal bronchi epithelium) cells. Expression levels of TCF-4 mRNA were examined using transcription-polymerase chain reaction (RT-PCR) in 9 lung cancer cell lines. Among 120 lung cancer specimens, 96 samples showed high expression of TCF-4 (80.0%), including 37 samples showed TCF-4 expression both in cytoplasm and nuclei (30.8%),TCF-4 were not detected in 10 corresponding normal lung specimens. TCF-4 expression level was positively correlated with TNM stages (P =0.022). The fluorescence signal of TCF-4 protein was conspicuous in lung cancer cells, primarily in cell nuclei, but extremely low in HBE. TCF-4 mRNA expression levels were incompatible in different histology types, the expression level of TCF-4 was relatively high in giant cell carcinoma cells, but low in lung adencarcinoma cells. High expression of TCF-4 positively correlated with lung cancer progression.

PI-3K/Akt Pathway-Dependent Cyclin D1 Expression Is Responsible for Arsenite-Induced Human Keratinocyte Transformation

BackgroundLong-term exposure of arsenite leads to human skin cancer. However, the exact mechanisms of arsenite-induced human skin carcinogenesis remain to be defined.ObjectivesIn this study, we investigated the potential role of PI-3K/Akt/cyclin D1in the transformation of human keratinocytic cells upon arsenite exposure.MethodsWe used the soft agar assay to evaluate the cell transformation activity of arsenite exposure and the nude mice xenograft model to determine the tumorigenesis of arsenite-induced transformed cells. We used the dominant negative mutant and gene knockdown approaches to elucidate the signaling pathway involved in this process.ResultsOur results showed that repeated long-term exposure of HaCat cells to arsenite caused cell transformation, as indicated by anchorage-independent growth in soft agar. The tumorigenicity of these transformed cells was confirmed in nude mice. Treatment of cells with arsenite also induced significant activation of PI-3K and Akt, which was responsible for the anchorage-independent cell growth induced by arsenite exposure. Furthermore, our data also indicated that cyclin D1 is an important downstream molecule involved in PI-3K/Akt–mediated cell transformation upon arsenite exposure based on the facts that inhibition of cyclin D1 expression by dominant negative mutants of PI-3K, and Akt, or the knockdown of the cyclin D1 expression by its specific siRNA in the HaCat cells resulted in impairing of anchorage-independent growth of HaCat cells induced by arsenite.ConclusionOur results demonstrate that PI-3K/Akt–mediated cyclin D1 expression is at least one key event implicated in the arsenite human skin carcinogenic effect.

The Tyrosine Kinase, Pyk2/RAFTK, Mediates LPS-Induced IL-8 and MCP-1 Expression in Human Endothelial Cells.

Lipopolysaccharide (LPS), an essential component of the surface of Gram-negative bacteria, has been shown to induce various inflammatory cytokines, including IL-8 and MCP-1, in endothelial cells. However, the mechanism by which LPS mediates the production of these inflammatory cytokines is not well known. In the present study, we investigated the role of proline-rich tyrosine kinase 2 (Pyk2), also known as RAFTK, in LPS-induced IL-8 and MCP-1 expression in endothelial cells. We observed the concentration-dependent and time-dependent tyrosine phosphorylation of Pyk2 following LPS treatment in human umbilical vein endothelial cells (HUVEC). We next analyzed the site of Pyk2 phosphorylation using antibodies specific to the individual phosphorylated tyrosine residues in Pyk2: pY402 (Src binding site), pY881 (Grb2 binding site) and pY580 (autophosphorylation site). LPS stimulation significantly enhanced phosphorylation of the pY402 and pY580 residues, but not of the pY881 site. The role of Pyk2 in LPS-induced IL-8 and MCP-1 expression was further investigated using a recombinant adeno-associated virus (AAV) expressing kinase-defective mutant Pyk2. Endothelial cells infected with the catalytically inactive Pyk2 mutant significantly attenuated LPS-induced IL-8 and MCP-1 production in HUVEC, compared to cells infected with the control AAV vector. Treatment of endothelial cells with a specific inhibitor of Pyk2, Tyrphostin A9, also blocked the expression of IL-8 and MCP-1 in a dose-dependent manner. Both p42/p44 and p38 MAP kinase pathways have been implicated in the production of inflammatory cytokines in endothelial cells. We found that blocking of Pyk2 using Tyrphostin A9 inhibited the phosphorylation of p38 MAP kinase but merely altered the kinetics of p42/p44 MAPK phosphorylation, indicating that p38 MAP kinase is an important downstream molecule of Pyk2 in LPS-induced IL-8 production. The involvement of the p38 MAP kinase pathway was confirmed by the dose-dependent blocking of IL-8 production upon treatment with a specific inhibitor of p38 MAP kinase. In summary, our data illustrate a key role for Pyk2 in LPS-mediated signaling, resulting in IL-8 and MCP-1 secretion in human endothelial cells. These findings may have important implications for the treatment of sepsis and other inflammatory disorders.

Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy

To evaluate the prognostic significance of thymidine phosphorylase (TP) and coexpression of cyclooxygenase-2 (COX-2)/TP, and to investigate the relationship between COX-2 and TP expression in squamous cell carcinoma of the uterine cervix. Cancer specimens from 75 patients with International Federation of Gynecology and Obstetrics Stage IIB squamous cell carcinoma of the uterine cervix who had undergone radiotherapy and concurrent chemotherapy were immunohistochemically stained with COX-2 and TP antibodies and scored. The prognostic significance of their expression status, and the relationship between COX-2 and TP was investigated. TP predominantly stained cytoplasm and the cell membrane of the tumor cells mainly in a diffuse and intense manner. TP was negative (<10% distribution) in 17%, 1+ (10-50%) in 25%, and 2+ (>50%) in 57% of patients. TP overexpression was related to a marginal prognostic significance of a poor 5-year overall survival (p = 0.082, log-rank test) and a high locoregional recurrence rate (p < 0.1, chi-square test). COX-2 and TP coexpression was observed in 24% of patients and was significantly related to poor 5-year disease-free and overall survival rates (p = 0.0083 and p = 0.025, respectively), a high pelvic lymph node involvement rate, a poor response to treatment, and a greater incidence of locoregional recurrence (p < 0.05). By multivariate analyses, only COX-2, TP, and coexpression of COX-2/TP were significant independent prognostic indicators of patient survival. All tumors showed 1+ or 2+ TP expression when COX-2 was positive, and no tumor expressed COX-2 when TP was negative (p = 0.03). In contrast, 77% of tumors expressed 1+ or 2+ TP without the synchronous expression of COX-2. Thymidine phosphorylase expression or COX-2/TP coexpression may be used as a molecular prognostic marker for squamous cell carcinoma of the uterine cervix. TP appears to be an important downstream molecule of COX-2 during angiogenesis and may be a new target for the treatment of uterine cervical cancer.

3-OH flavone inhibition of epidermal growth factor-induced proliferaton through blocking prostaglandin E2 production.

Epidermal growth factor (EGF) has been shown to induce proliferation in cells, however, the role of prostaglandin E(2) (PGE(2)) plays in EGF-induced proliferation in still unclear. EGF and PGE(2) showed proliferation responses in epidermoid carcinoma cell A431 by MTT and [(3)H] thymidine incorporation assay. Activation of the EGF receptor and extracellular signal-regulated protein kinases (ERK1/2), but not p38 and JNK, appeared 10 min after EGF treatment, whereas total amounts of ERK1/2, p38 and JNK remained unchanged in A431 cells, accompanied by induction of COX-2 and PGE(2) production. PD98059, a specific ERK1/2 inhibitor, inhibited EGF-induced proliferation with concomitant decreases in ERK1/2 phosphorylation and COX-2/PGE(2) induction. Non-steroid anti-inflammatory drugs (NSAIDs) such as aspirin and diclofenac, a COX activity inhibitor, inhibited EGF-induced proliferation by blocking PGE(2) production. The addition of PGE(2) reversed the inhibitory effects of PD98059, aspirin, and diclofenac on EGF-induced proliferation. This suggests that COX-2/PGE(2) activation involves in EGF-induced proliferation and locates at the downstream of ERK1/2 activation. Furthermore, the natural product, 3-OH flavone, showed the most-potent inhibitory activity on EGF-induced proliferation among 9 structurally-related compounds, and suppression of EGF receptor phosphorylation, ERK1/2 phosphorylation, and COX-2/PGE(2) production by 3-OH flavone was identified. PGE(2) addition attenuates the inhibitory activity of 3-OH flavone on EGF-induced proliferation by MTT assay and colony formation by soft agar assay. Additionally, 3-OH flavone also showed more-specific inhibition on EGF- than on fetal bovine serum (FBS)-induced proliferation in A431 cells. Results of our present study provide evidence to demonstrate that PGE(2) is an important downstream molecule in EGF-induced proliferation, and 3-OH flavone, which inhibits PGE(2) production by blocking MAPK cascade, might reserve potential for development as an anti-cancer drug.

Expression of OASIS, a CREB/ATF family transcription factor, in CNS lesion and its transcriptional activity

We reported the expression patterns of a novel member of the CREB/ATF family, OASIS, in central nervous system (CNS) lesions and its transcriptional activity. OASIS gene expression was upregulated in the stab-injured spinal cord. Double labeling experiments revealed that the distribution of OASIS mRNA-positive cells overlapped with a population of GFAP-immunoreactive cells. This finding suggested that OASIS might regulate expression of important downstream molecules in certain subset of the reactive astrocytes (e.g. inhibitory substances in injured brain). In gel shift assays, OASIS was able to specifically bind to CRE as CREB family members were. We then examined transcriptional activity of full-length OASIS with GAL4-UAS-luciferase reporter assay in COS7 cells. OASIS protein activated transcription, but did not inhibit basal transcription driven by AdML promoter. To determine critical portion(s) of the OASIS protein in transcriptional activation, we examined the activity of various deletion constructs of OASIS gene. The assay revealed that a strong transcriptional activation domain lay in the N-terminal region where acidic amino acids clustered and a possible repression domain, which had not been reported for other CREB/ATF family members, lay in the more C-terminal region. We therefore proposed that OASIS protein positively regulated gene transcription in a subset of reactive astrocytes, and thereby influenced the reaction of injured CNS tissues.

Inhibition of Insulin-like Growth Factor-I-mediated Cell Signaling by the von Hippel-Lindau Gene Product in Renal Cancer

Insulin-like growth factor-I (IGF-I)-mediated signaling is thought to be involved in the regulation of multiple cellular functions in different tumors including renal cell carcinoma (RCC). Blocking IGF-I signaling by any of the several strategies abolishes or delays the progression of a variety of tumors in animal models. Herein, we demonstrate that in RCC cell lines, IGF-I-mediated signaling is found to be inhibited in the presence of wild type von Hippel-Lindau (VHL) tumor suppresser gene. Moreover, molecular modeling and biochemical approaches have revealed that beta-domain of the VHL gene product by interacting directly with protein kinase Cdelta inhibits its association with IGF-IR for downstream signaling. We also demonstrated that RCC has IGF-I-mediated invasive activity where protein kinase Cdelta is an important downstream molecule, and this invasiveness can be blocked by wild type VHL. These experiments thus elucidate a novel tumor suppresser function of VHL with its unique kinase inhibitory domain.